Bristol Myers Squibb Company (BMY) vs Pfizer Inc. (PFE)
Bristol Myers Squibb Company and Pfizer Inc. are both Drug Manufacturers General companies. Pfizer Inc. is the larger, with a market value of $161.7B against $125.9B — 1.3× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.8× against 37.7×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against −0.21%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 6.80%) and the higher return on invested capital (13.7% vs 6.30%). Both pay a dividend; Pfizer Inc. yields more (6.18% vs 5.04%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 15 and Pfizer Inc. on 8.
Valuation
Profitability
| Metric | BMY | PFE | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 73.18% | 72.77% |
| Operating margin | 24.22% | 21.70% | 18.90% |
| Net margin | 18.87% | 6.80% | 8.27% |
| Free cash flow margin | 23.26% | 17.25% | 17.25% |
| Return on equity | 46.63% | 4.97% | 6.97% |
| Return on assets | 10.18% | 2.13% | 2.76% |
| Return on invested capital | 13.69% | 6.30% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack